Shattuck Labs (NASDAQ:STTK) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Shattuck Labs (NASDAQ:STTK) released its quarterly earnings data on Thursday. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%.

Shattuck Labs Stock Down 3.4 %

STTK stock opened at $1.14 on Friday. The company has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.51. The company has a market capitalization of $54.42 million, a P/E ratio of -0.75 and a beta of 1.66. Shattuck Labs has a fifty-two week low of $0.94 and a fifty-two week high of $11.76.

Analyst Upgrades and Downgrades

STTK has been the topic of several research reports. Leerink Partners started coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective on the stock. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.